Publié le vendredi 3 décembre 2004 | http://prison.rezo.net/2004-01-hiv-seroprevalence-in/
HIV Seroprevalence in Prisons Canadian federal prisons Canadian provincial prisons A study released in 2004 of 1,617 prisoners in 7 provincial institutions in Québec found an HIV seroprevalence rate of 2.3 percent among men and 8.8 percent among women. In British Columbia, a study conducted in all adult BC provincial prisons in 1993 found an HIV seroprevalence rate of 1.1 percent. The study has not been repeated, but in 1996 a review of known cases alone revealed rates ranging from two to 20 percent in various prisons. Many of those who are HIV-positive in prison were already living with the virus on the outside. Indeed, the highest rates of HIV infection in prisons can be found in areas where rates of HIV infection are high among injection drug users in the community. Commenting on the situation in the United States, the US National Commission on AIDS stated that “by choosing mass imprisonment as the ... governments’ response to the use of drugs, we have created a de facto policy of incarcerating more and more individuals with HIV infection.” HIV infection rates are high in many prison systems. In Western Europe, particularly high rates have been reported in Portuguese (20 percent) and Spanish prisons (16.6 percent). Rates are also high in countries such as Switzerland (4 to 12 percent) and Italy (7 percent). In Eastern Europe, 7 percent of Ukrainian prisoners and 15 percent of Lithuania prisoners are HIV-positive. Forty-one percent of South African prisoners are reported to be HIV positive. In Latin America, high rates of HIV infection have been found in Brazil (10.9 - 21.5 percent) and Honduras (7 percent). In contrast, relatively low rates of HIV prevalence have been reported from Australia. In the United States, the geographic distribution of cases of HIV infection and AIDS is remarkably uneven. Many systems continue to have rates under one percent, while in a few rates approach 10 percent among men and 15 percent among women. Hepatitis C Seroprevalence Rates continue to rise. In one federal prison, 33 percent of study participants tested positive in 1998, compared with 27.9 percent in 1995. In 2002, 3,173 federal prisoners were known to be HCV positive : 25.2 percent of male and 33.7 percent of female prisoners. Worldwide Potential for further spread Additional Reading GE Macalino et al. Hepatitis C infection and incarcerated populations. International Journal of Drug Policy 2004 ; 15 : 103-114. A review of prevalence and incidence of HCV in prisons worldwide. R Elliott. Prisoners’ Constitutional Right to Sterile Needles and Bleach. Appendix 2 of R Jürgens. HIV/AIDS in Prisons : Final Report. Montréal : Canadian HIV/AIDS Legal Network & Canadian AIDS Society, 1996, at 3-4. Provides a summary of early Canadian seroprevalence studies in prisons. Available at www.aidslaw.ca/Maincontent/issues/prisons/APP2.html. C Hankins et al. HIV-1 infection in a medium security prison for women - Quebec. Canada Diseases Weekly Report 1989 ; 15(33) : 168-170. The first HIV seroprevalence study in a Canadian prison. S Landry et al. Étude de prévalence du VIH et du VHC chez les personnes incarcérées au Québec et pistes pour l’intervention. Canadian Journal of Infectious Diseases 2004 ; 15 (Suppl A) : 50A (abstract 306). The most recent Canadian study. Third, revised and updated version, 2004. Copies of this info sheet are available on the Network website at http://www.aidslaw.ca/Maincontent/issues/prisons.htm and through the Canadian HIV/AIDS Information Centre (email : aids/sida@cpha.ca). Reproduction of the info sheet is encouraged, but copies may not be sold, and the Canadian HIV/AIDS Legal Network must be cited as the source of this information. For further information, contact the Network (tel : 514 397-6828 ; fax : 514 397-8570 ; email : info@aidslaw.ca). Ce feuillet d’information est également disponible en français. Funded by Health Canada under the Canadian Strategy on HIV/AIDS. The findings, interpretations, and views expressed in this publication are entirely those of the author and do not necessarily reflect the official policy or positions of Health Canada.
|